Summary
Pfizer Inc. (PFE) has officially announced the completion of its acquisition of Seagen Inc. through a merger, effective December 14, 2023. This significant transaction involved Pfizer's wholly owned subsidiary, Aris Merger Sub, Inc., merging with and into Seagen, with Seagen now operating as a subsidiary of Pfizer. The acquisition details specify that each outstanding share of Seagen common stock was converted into a cash payment of $229.00 per share, subject to certain exceptions, and Seagen equity awards were also converted or adjusted accordingly.
Key Highlights
- 1Pfizer has successfully completed the acquisition of Seagen Inc. via a merger, effective December 14, 2023.
- 2The transaction sees Seagen become a wholly owned subsidiary of Pfizer.
- 3Seagen shareholders will receive $229.00 in cash for each share of Seagen common stock they held.
- 4Outstanding Seagen equity awards have been converted into cash-based awards or adjusted according to the merger agreement.
- 5This filing serves as an amendment to a previous report, confirming the completion of the merger.
- 6A press release dated December 14, 2023, was issued to announce the completion of the transaction.
Frequently Asked Questions
This 8-K/A filing serves to formally announce the completion of Pfizer's acquisition of Seagen Inc. through a merger, which became effective on December 14, 2023.
Pfizer acquired Seagen for $229.00 in cash for each outstanding share of Seagen common stock. Details regarding the treatment of Seagen equity awards are also outlined.
The merger officially became effective on December 14, 2023.
While this filing focuses on the completion of the transaction, the acquisition of Seagen is strategically significant for Pfizer, aimed at bolstering its oncology portfolio with Seagen's innovative cancer therapies, particularly in antibody-drug conjugates (ADCs).